Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

ATLANTA, May 15, 2012 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2012 and provided a business update.

"We are delighted with recent developments that have strengthened and advanced our HIV/AIDS vaccine program," said Chairman of the Board David Dodd. "Our Phase 1/2 therapeutic vaccine trial continues to enroll patients and we expect full enrollment by the end of 2012. The HIV Vaccine Trials Network (HVTN) continues toward the goal of compiling the data for the Phase 2a trial of our preventive vaccine by the end of 2012 and recently opened a new Phase 1 trial of the next generation of our preventive vaccine, which utilizes granulocyte-macrophase colony-stimulating factor (GM-CSF) as an adjuvant to boost the immune response. We are gratified that the NIH-supported HVTN continues to recognize the potential life-saving value of our vaccine technology and has committed substantial resources toward advancing our clinical progress. Most important, we have a highly competent and dedicated team, focused on excellence in execution related to our ongoing development programs."

Robert T. McNally, PhD, GeoVax President and CEO, remarked, "We are particularly pleased with the outstanding preclinical results we recently reported for our next generation preventive vaccine, which co-expresses GM-CSF as an adjuvant in the DNA vaccine used to prime the immune system. Our studies demonstrated an unprecedented 90% reduction in per exposure risk of transmission for the E660 strain of SIV (simian HIV) and 72% reduction in per exposure risk of transmission for SIV251, the most potent strain of SIV used in non-human primate models. These are extremely rigorous models, with the primates receiving repeated weekly exposures to SIV of up to 300 times the amount one would expect to see in humans. Our data ind
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Electrocardiogram (ECG) Devices - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... million by 2016. The North America ... market share while Europe claims ...
(Date:12/15/2014)... , December 15, 2014 BerGenBio ... for aggressive drug resistant cancers, today announces that it ... private placing from new and existing investors. ... support the development of its pipeline of innovative cancer ... its lead drug candidate, BGB324, a first-in-class selective Axl ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , Dec. 15, ... Sanofi US (EURONEXT: SAN and NYSE: SNY) are collaborating ... launch Cholesterol Counts , an awareness program that ... numbers, and the risks associated with high LDL-C (bad ... CholesterolCounts .com to take a brief poll and ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... ... 2009. , ... October 16, 2009 -- Tony Rico has recently been promoted to Senior Vice President of ... promotion was effective September 1, 2009. , , , , ,"This position has ...
... A bioethicist who specializes in moral dilemmas families face ... honored with the first-ever March of Dimes Distinguished Lectureship ... a nationally-recognized pediatrician and ethicist, will deliver his lecture ... the American Society of Bioethics and Humanities, 11th annual ...
... Feature Gena Rowlands , EAST BRUNSWICK, N.J., Oct. 15 ... home to New Jersey to host a celebrity cocktail reception ... will raise money for National MS Society,s New Jersey Metro ... Jersey, where it is estimated that almost 10,000 people have ...
... 15 ResMed Inc. (NYSE: RMD ), announced today that ... the first quarter of fiscal year 2010, ended September 30, 2009. ... p.m. Pacific Time and the Company will host a conference call ... , The conference call is scheduled to begin at 1:30 p.m. ...
... AUSTIN, Texas, Oct. 15 deverus, inc., a ... for background screening companies, announced today that Corporate ... deverus, Verocity 2009 software platform to provide an ... An affiliate of Corporate Research and Investigations (Pvt.) ...
... WASHINGTON, Oct. 15 A National Awareness Campaign to ... Arabia to coincide with international Breast Cancer Awareness month. The campaign ... of the Zahra Breast Cancer Association and wife of the ... , and Princess Rima bint Abdullah bin Abdulaziz. It officially ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 3Health News:East Brunswick Native Returns Home to Help New Jersey Residents Living with MS 2Health News:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results 2Health News:deverus(TM) Expands Operations Overseas 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: